表面增强激光解吸电离飞行时间质谱技术筛查肺癌血清特异性蛋白质及其临床意义

目的:探讨用表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)技术筛查肺癌血清特异性蛋白质的临床意义。方法:应用SELDI-TOF-MS对35例正常对照组、43例治疗前肺癌病人的血清样品进行蛋白质指纹图谱测定,用BioMarker Wizard 3．01及BioMarker Parrern System 5．01分析软件对测得的数据进行处理及建立诊断模型。结果:共检测到251个蛋白质峰,筛选出差异蛋白质峰11个,以质荷比(m/z)分别为M2799_26,M3227_41,M5739_70和M8164_30的4个蛋白质峰为依据组合构建分类决策树模型,分出5个终节点。决策树模型的原始判别总准确率为91．0%(71/78),敏感性为88．4%(38/43),特异性为94．3%(33/35);交叉验证总准确率为85．9%(67/78),敏感性为88．4%(38/43),特异性为82．9%(29/35)。结论:SELDI-TOF-MS在肺癌血清特异性蛋白质的筛选及诊断模型的建立有一定的临床意义。

Detection and Clinical Significance of Serum Proteomic Patterns of the Patients with Lung Cancer by Surface Enhanced Laser Desorption/Ionization-time of Flight-mass Spectrometry

Objective:To detect the serum proteomic patterns in lung cancer by surface enhanced laser desorption/ ionization-time of flight-mass spectrometry (SELDI-TOF-MS) protein chip array techniques,screen biomarkers of lung cancer and build diagnostic models in order to evaluate their clinical significance.Methods:SELDI-TOF-MS and CM-10 protein chip were used to detea the serum proteomic patterns of 43 patients with lung cancer before radiotherapy combined chemotherapy,37 patients with lung cancer after radiotherapy combined chemotherapy and 35 normal control subjects.BioMarker Wizard 3.01 and BioMarker Parrern System 5.01 were used in combination to analyze the data and to develop diagnostic models.Results:Ten protein peaks from a total of 251 were automatically chosen as a biomarker pattern in the training set.These peaks were changed after radiotherapy combined chemotherapy,and the changes weren't remarkably between the treated set and normal control set. Among them four protein peaks pattern (M2799_26,M3227_41,M5739_70 and M8164_30 mass/charge ratio[m/z]) was observed in the model that could used to distinguish lung cancer from non cancerous diseases.It yielded a sensitivity of 88.4%(38/43) and a specificity of 94.3%(33/35).When the SELDI marker pattern was tested with the blinded test set,it yielded a sensitivity of 88.4% (88/40)and a specificity of 82.9%(29/35).Conclusions:These results suggest that serum SELDI protein profiling can distinguish lung cancer patients from normal subjects with relatively high sensitivity and specificity,and the SELDI-TOF-MS is a potential tool for the screening of lung cancer.